Dolutegravir plus rilpivirine: benefits beyond viral suppression
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000029252
Abstract: Abstract Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and… read more here.
Keywords: cd4 cd8; cell count; cell; plus rilpivirine ... See more keywords
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
Sign Up to like & getrecommendations! Published in 2023 at "Viruses"
DOI: 10.3390/v15040936
Abstract: Background: The high effectiveness and safety of the two-drug (2DRs) strategy using dolutegravir (DTG) plus lamivudine (3TC) have led to international guidelines recommending their use for treatment-naive HIV patients. In virologically suppressed patients, de-escalating from… read more here.
Keywords: virologically suppressed; safety; hiv; dtg plus ... See more keywords